4basebio and Genezen Collaborate on Synthetic DNA for Viral Vector Manufacturing
4basebio and Genezen will combine synthetic DNA technology with viral vector development expertise to advance gene therapy manufacturing from early stages through commercial production.
Technology firms 4basebio of the United Kingdom and Genezen of the United States have entered into a strategic collaboration aimed at advancing the manufacturing of next-generation viral vectors using synthetic, cell-free DNA platforms.
The commercial collaboration merges 4basebio's advanced synthetic DNA technology with Genezen's expertise in viral vector development and manufacturing. The partnership is intended to support gene therapy programs across their entire lifecycle, from early-stage development through clinical and commercial production.
"The collaboration with Genezen is a significant step forward in leveraging the potential of our cell-free DNA platforms," stated 4basebio CEO and Chairman Søren Lynggård Hansen. "We can now offer our clients an integrated solution that streamlines gene therapy production."
Genezen CEO Kirk Jackson expressed excitement about joining forces with 4basebio. "This partnership will accelerate the development and manufacturing of gene therapies, ultimately benefiting patients who require these groundbreaking treatments."
The collaboration is expected to speed up the market entry of gene therapies while enhancing the efficiency and scalability of manufacturing processes.